A new system for isolating rare circulating tumor cells (CTCs) -- living solid tumor cells found at low levels in the bloodstream -- shows significant improvement over previously developed devices and does not require prior identification of tumor-specific target molecules. Developed at the Massachusetts General Hospital (MGH) Center for Engineering in Medicine and the MGH Cancer Center, the device rapidly delivers a population of unlabeled tumor cells that can be analyzed with both standard clinical diagnostic cytopathology and advanced genetic and molecular technology.
For further study visit : http://www.sciencedaily.com/releases/2013/04/130403141436.htm
